The purpose of these studies was to assess the role of vasopressin in maintaining supine and upright blood pressures in hypertensive diabetic subjects. Patients with (0 = 6) or without (n = 10) evidence of autonomJc insufficiency had blood pressure and heart rate monitored before and after receiving an intravenous injection of 0.5 mg of a V, vasopressin Inhibitor. None of the patients had supine changes in blood pressure or heart rate. However, upon assuming the erect position, the six patients with preexisting orthostatic hypotension had an average blood pressure fall of 44 mm Hg after vasopressin inhibition (as opposed to 20 mm Hg before), accompanied by a modest rise in heart rate of 20 beats/min. Those without autonomic dysfunction were separated into two subgroups. Four developed an average fall in orthostatic blood pressure of 18 mm Hg after vasopressin inhibition, whereas the remaining six had no change. There were no distinguishing hormonal characteristics (vasopressin, renin, and catecholamine levels) between the groups, but in the patients with autonomic dysfunction, the renin level failed to rise when upright. We conclude that vasopressin plays an important role in preventing or minimizing orthostatic hypotension in diabetic patients. Its pressor contribution is crucial in those with autonomic insufficiency and impaired renin and sympathetic responses, in whom the pressor effectiveness of vasopressin is greatly enhanced. 12 Indeed, under normal conditions, the sympathetic nervous system appears to play by far the most prominent role in sustaining BP, with the renin-angiotensin system and AVP acting as important backup mechanisms.
SUMMARY
The purpose of these studies was to assess the role of vasopressin in maintaining supine and upright blood pressures in hypertensive diabetic subjects. Patients with (0 = 6) or without (n = 10) evidence of autonomJc insufficiency had blood pressure and heart rate monitored before and after receiving an intravenous injection of 0.5 mg of a V, vasopressin Inhibitor. None of the patients had supine changes in blood pressure or heart rate. However, upon assuming the erect position, the six patients with preexisting orthostatic hypotension had an average blood pressure fall of 44 mm Hg after vasopressin inhibition (as opposed to 20 mm Hg before), accompanied by a modest rise in heart rate of 20 beats/min. Those without autonomic dysfunction were separated into two subgroups. Four developed an average fall in orthostatic blood pressure of 18 mm Hg after vasopressin inhibition, whereas the remaining six had no change. There were no distinguishing hormonal characteristics (vasopressin, renin, and catecholamine levels) between the groups, but in the patients with autonomic dysfunction, the renin level failed to rise when upright. We conclude that vasopressin plays an important role in preventing or minimizing orthostatic hypotension in diabetic patients. Its pressor contribution is crucial in those with autonomic insufficiency and impaired renin and sympathetic responses, in whom the pressor effectiveness of vasopressin is greatly enhanced. T HE systemic pressor action of arginine vasopressin (AVP) does not seem to contribute to normal blood pressure (BP) maintenance in the resting, intact, well-hydrated subject. 12 Indeed, under normal conditions, the sympathetic nervous system appears to play by far the most prominent role in sustaining BP, with the renin-angiotensin system and AVP acting as important backup mechanisms.
3 " 6 Under conditions of impaired sympathetic function, each of these systems can assume a major role and can, after a transient drop, restore BP to baseline, whereas concurrent elimination of all three causes prolonged hypotension.
Long-standing diabetes mellitus frequently leads to autonomic insufficiency of various degrees. One of the earliest signs of this condition is orthostatic intolerance. Since older persons with diabetes are also known to have characteristically unresponsive renin-arigiotensin systems, 7 AVP would be expected to play a major role in maintaining their BP. The purpose of the present study was to assess the pressor contribution of AVP in sustaining the supine and upright BP of diabetic patients with and without signs of orthostatic intolerance.
Subjects and Methods
Sixteen patients with Type II (non-insulin-dependent) diabetes mellitus and supine mild to moderate hypertension without medication (diastolic BP 95-105 mm Hg) were recruited for this study after giving written, informed consent. They were separated into two groups: those with preexisting orthostatic hypotension (diastolic BP fall by > 10 mm Hg, n = 6) and those without known orthostatic hypotension (n = 10).
During the first hour of the 5'/2-hour protocol the patients lay in bed, and the mean BP of this period was taken as baseline. Next, they assumed the upright position for 30 minutes (BP preupright), followed by another hour of supine BP measurements (BP presupine). At that point they received an intravenous injection of 0.5 mg of the V, AVP inhibitor [l-(j3-mercapto-/3,/3-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine]AVP 8 '' and remained supine for another hour (BP postsupine). Subsequently, they were allowed to stand again and walk around for 2 hours, during which they could sit intermittently but not lie in bed (BP postupright). A blood sample was drawn at the end of each period before changing posture, for a total of four samplings for plasma renin activity (PRA), 10 catecholamines," and AVP. Statistical evaluation within groups was performed by Student's t test for paired data or by analysis of variance for repeated measures. Among groups, either Student's t test for independent samples or the MannWhitney test was performed. Results are reported as means ± SEM; differences were considered significant when p was less than 0.05. Table 1 shows the clinical characteristics of the 16 participants. Those with preexisting orthostatic hypotension were classified as Group I and those without orthostatic hypotension as Group II. The latter were separated into two distinct subgroups, one with minimal upright BP change after AVP inhibition (lib, n = 6) and one with significant orthostatic BP fall (Ha, n = 4), although somewhat less pronounced than that of patients in Group I. These BP changes are shown graphically in Figure 1 . The supine mean BPs before AVP inhibition were similar in both groups and remained unchanged after administration of the AVP inhibitor. Table 2 shows the heart rates at each stage of the protocol. The orthostatic increase in heart rate after AVP inhibition was similar in all three groups, despite the widely different concurrent changes in BP; however, the difference in orthostatic heart rate rise before and after AVP inhibition was significant only in the autonomically intact patients of Group II. Table 3 shows the hormonal changes in the two groups in supine and upright positions, before and after administration of the AVP inhibitor. As expected, the level of norepinephrine increased with upright posture and PRA tended to increase. After AVP inhibition the response of PRA levels to posture was greatest in patients without orthostatic intolerance (Group II). 
Results

Discussion
These experiments demonstrated that in hypertensive diabetic patients with some degree.of autonomic insufficiency, as indicated by preexistence of mild orthostatic hypotension, AVP plays an important role in maintaining BP in the upright posture. These patients (Group I) had an average mean postural BP drop of 20 mm Hg before inhibition of AVP, which was further accentuated to an average drop of 44 mm Hg after inhibition of AVP. The 10 patients with no preexisting signs of autonomic insufficiency displayed two distinct responses: six had no orthostatic BP change either before or after inhibition of AVP (Group lib), whereas four, who also had no orthostatic change before AVP inhibition (Group Ila), did display a significant orthostatic BP fall by an average of 18 mm Hg after AVP inhibition. There were no distinguishing clinical features between the two subgroups, although Group Ha patients, in whom postural hypotension developed only after AVP inhibition, tended to have somewhat longer duration of diabetes. Patients in Group I tended to be older than those in Group II and had significantly longer duration of diabetes, suggesting that the most relevant clinical factor that makes diabetic persons prone to autonomic dysfunction and postural hypotension is the duration of the disease.
Although the orthostatic increases in heart rate after administration of the AVP antagonist were similar in all groups, they corresponded to very different patterns of BP response. The average 22 beats/min rise in Group II was appropriate for subjects who had no BP fall with orthostasis or only a small orthostatic fall. However, a similar rise in Group I was grossly inadequate for patients who exhibited an average orthostatic BP fall of 50 mm Hg; this indicates diminished baroreceptor reflex response, compatible with the existing autonomic dysfunction in these subjects and probably further aggravated by the loss of the sensitizing effect of AVP on the baroreceptors. Values are means ± SE. NE = norepinephrine; E = epinephrine; Pre = before AVP inhibition; Post = after AVP inhibition; S = supine; U = upright.
•p<0.05, S vs U; tp<0.05, Group I vs Group II.
The only apparent hormonal difference between the two groups was in the level of PRA, which tended to be lower in Group I at rest and was unable to respond to the potent stimulus of postural BP fall after administration of the AVP inhibitor. Hyporeninemic hypoaldosteronism is a common feature of older persons with long-standing diabetes. 7 Loss of the backup pressor contribution of reactive hyperreninemia 14 is probably an important factor further aggravating the orthostatic BP fall in these patients.
It was surprising that plasma norepinephrine levels were not significantly different between the two groups; in fact, upright norepinephrine tended to increase more in Group I patients with documented autonomic insufficiency and major hypotensive response. It is possible that these levels might have been much higher in response to a BP drop of this magnitude if the sympathetic system had been intact in these patients. It is also likely that their vascular a-adrenergic receptor function was diminished due to loss of numbers or sensitivity and therefore unable to produce adequate vasopressor response.
A most interesting finding was the lack of difference in AVP levels, whether supine or upright, between the two groups, even though the pressor contribution of AVP was very important in Group I and minimal to absent in Group II. This is in accordance with the extensive evidence in the literature concerning animals and humans, which indicates that the pressor effectiveness of AVP is maximal under conditions of impaired sympathetic activity or impaired baroreceptor reflexes.
3 " 6 15 - 18 The upright AVP levels in Group I might have been expected to be higher in response to the orthostatic BP drop. Indeed, in subjects with intact sympathetic systems submitted to selective decrease of central blood volume and right atrial stretch without change in systemic volume or hydroosmotic status (e.g., by lower body negative pressure or tilting" 20 ), AVP release is stimulated and plays a major hemodynamic role in restoring the compromised circulation.
Another intriguing finding in the present study was the time course of the BP responses to AVP inhibition. As shown in Figure 1 , patients who exhibited a significant orthostatic drop in BP after AVP inhibition did not do so immediately upon assuming the upright posture. The hypotension actually occurred about 1 hour after orthostasis and ambulation (i.e., approximately 2 hours after intravenous administration of the AVP antagonist) and continued for an additional hour of observation, after which it started returning toward the baseline. This time course cannot be easily explained by a mechanism of direct competitive inhibition of AVP at the vascular wall V.-receptor level. It therefore appears likely that the antagonist acted either on the baroreceptors to eliminate the AVP-induced sensitization gradually, 21 or through a central nervous system-mediated mechanism. The latter could desensitize baroreceptor reflexes, 22 modulate central sympathetic responses, 23 or otherwise affect the central pressor actions of AVP. 24 At this point it is not clear whether peripherally circulating AVP or its peptide analogues can cross the blood-brain barrier; however some brain regions relevant to the central action of AVP, such as the area postrema and the organum vasculosum of the lamina terminalis, 25 are believed to lie outside the blood-brain barrier and would therefore be within reach of circulating AVP or its peptide analogues regardless of the ability of these compounds to penetrate other brain regions. It is possible then that the delay in the postural effects of the AVP antagonist may represent the time necessary to interfere with the function of central vasopressinergic neurons.
In conclusion, the present study demonstrates the crucial role of AVP in preventing or minimizing orthostatic hypotension in diabetic hypertensive subjects. This role is even more important in those with some degree of autonomic dysfunction in whom the vasopressor contributions of both the renin-angiotensin and the sympathetic nervous systems are diminished whereas the pressor effectiveness of AVP is greatly enhanced.
